OncRef

Clinical Trial: NCT05401786

Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:The Netherlands Cancer Institute
Information Provided By:The Netherlands Cancer Institute
Last Update Posted:2026-03-12

Study Overview

Brief Summary

Still many advanced non-small cell lung cancer (NSCLC) patients do not benefit from PD-(L)1 inhibition or will eventually develop progression through secondary resistance. Inhibition of CTLA-4, application of radiotherapy together with PD-1 inhibition showed synergistic effects and is deemed safe.

Official Title

Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC

Conditions

Carcinoma, Non-Small-Cell Lung

Intervention / Treatment

  • Drug: Ipilimumab
  • Drug: Cemiplimab
  • Radiation: SBRT

Other Study ID Numbers

  • M21RAD

Start Date (Actual)

2023-01-03

Primary Completion Date (Actual)

2024-11-15

Study Completion Date (Estimated)

2026-06

Enrollment (Estimated)

54

Study Type

Interventional

Phase

Phase 2